Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Reaffirmed by Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report published on Monday, Benzinga reports. They currently have a $25.60 price objective on the stock, down from their prior price objective of $26.00.

Several other equities research analysts have also weighed in on DCPH. Jonestrading restated a hold rating and issued a $25.60 target price on shares of Deciphera Pharmaceuticals in a report on Monday. Stifel Nicolaus lifted their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a buy rating in a research report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. lifted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a neutral rating in a research report on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $23.87.

Deciphera Pharmaceuticals Price Performance

Shares of Deciphera Pharmaceuticals stock opened at $25.28 on Monday. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -11.04 and a beta of 0.39. Deciphera Pharmaceuticals has a 52-week low of $9.90 and a 52-week high of $25.40. The stock has a 50-day simple moving average of $15.78 and a 200-day simple moving average of $14.45.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business had revenue of $48.30 million during the quarter, compared to analyst estimates of $45.93 million. During the same period in the previous year, the company earned ($0.60) EPS. The firm’s revenue was up 32.9% on a year-over-year basis. As a group, equities research analysts predict that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C increased its position in shares of Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock valued at $87,738,000 after purchasing an additional 190,580 shares during the period. Armistice Capital LLC increased its position in shares of Deciphera Pharmaceuticals by 12.7% during the fourth quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $83,876,000 after purchasing an additional 588,000 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Deciphera Pharmaceuticals by 14.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after purchasing an additional 290,968 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Deciphera Pharmaceuticals by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock valued at $25,191,000 after purchasing an additional 92,410 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its position in shares of Deciphera Pharmaceuticals by 176.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock valued at $16,482,000 after purchasing an additional 651,800 shares during the period. 70.96% of the stock is owned by institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.